Under_maintenance@stenvall-skoeld.com
M&A and Strategic Advisory firm Stenvall Skoeld & Company
  • About Us
    • Leadership
    • Locations
  • Services
    • Mergers & Acquisitions
      • Buy Side M&A Advisory
      • Sell Side M&A Advisory
    • Strategic Advisory & Research
  • Industries
    • Chemicals and Basic Materials
    • Consumer and Retail
    • Energy and Environment
    • Food and Agribusiness
    • Healthcare
    • Industrials
    • Technology, Media and Telecom
  • Careers
  • Contact
Select Page
China’s private healthcare industry in fundraising mode

China’s private healthcare industry in fundraising mode

by Nick Van Loocke | Mar 15, 2015 | China M&A, China Private Equity, Domestic Consumption, Healthcare, SSCO Newsletters

This post was originally published in the December 2013 issue of our healthcare newsletter China Healthcare Deals+Strategies. Subscribe (email) to our newsletter to learn more about our perspectives and insights on China’s healthcare sector. China’s emerging...
Q&A: China’s Role in the Global Biotech Industry

Q&A: China’s Role in the Global Biotech Industry

by Nick Van Loocke | Jan 25, 2015 | China Private Equity, Front Page, Healthcare, SSCO Newsletters

This post was originally published in the September 2014 issue of our healthcare newsletter China Healthcare Deals+Strategies. Subscribe (email) to our newsletter to learn more about our perspectives and insights on China’s healthcare sector. China’s Role in the...
Q&A: China’s Role in the Global Biotech Industry

mHealthcare in China: Giants join tech entrepreneurs seeking growth

by Carl-Johan Skoeld | Sep 28, 2014 | China M&A, China Private Equity, Consumer & Retail, Healthcare, SSCO Newsletters, TMT

This post is a longer version of an article originally published in the September 2014 issue of our healthcare newsletter China Healthcare Deals+Strategies. Subscribe (email) to our China healthcare newsletter. The Mobile Health Opportunity Mobile health (mHealth)...
Healthcare industry consolidation: The rise of Chinese M&A funds

Healthcare industry consolidation: The rise of Chinese M&A funds

by Carl-Johan Skoeld | Jun 10, 2014 | China M&A, China Outbound M&A, China Private Equity, Healthcare, SSCO Newsletters

This post was originally published in the June 2014 issue of our healthcare newsletter China Healthcare Deals+Strategies. Subscribe (email) to our newsletter to learn more about our perspectives and insights on China’s healthcare sector. Healthcare industry...
China’s private healthcare industry in fundraising mode

Strategic implications of China’s healthcare reform

by Carl-Johan Skoeld | Aug 26, 2013 | China M&A, China Outbound M&A, China Private Equity, General, Healthcare, SSCO Newsletters

This post was originally published in August issue of our healthcare newsletter China Healthcare Deals+Strategies. Subscribe (email) to our newsletter to learn more about our perspectives and insights on China’s healthcare sector. Medical devices: Strategic...
China PE Due Diligence Best Practice: The Human Factor

China PE Due Diligence Best Practice: The Human Factor

by Carl-Johan Skoeld | May 1, 2013 | China Due Diligence, China Private Equity, Front Page

  Contact us if you are interested in the full China PE Due Diligence Best Practice report This is the fifth and final article in our series on how the most effective private equity firms approach due diligence in China. 1. Independent due diligence Hire due diligence...
« Older Entries
  • Services
    • Mergers & Acquisitions
    • Buy Side M&A Advisory
    • Sell Side M&A Advisory
    • Capital Raising
    • Strategy & Research
  • Industries
    • Chemicals
    • Consumer and Retail
    • Energy and Environment
    • Food and Agribusiness
    • Healthcare
    • Industrials
    • TMT

SSCO Shanghai Head Office



Stenvall Skoeld & Company (China) Limited
4th Floor 139 No. 1 Ruijin Road
Huangpu District, Shanghai

Tel: +86 (21) 6136 6008
  • English
  • 中文
© Copyright 2021 Stenvall Skoeld & Company